bpc-157 resource vs TB-500: Complete Comparison (2026) Sublingual BPC-157 - TruHealth Physical

In the STEP 1 trial, semaglutide led to an average 14.9% reduction in body weight over 68 weeks , far outperforming placebo (NEJM study on semaglutide for weight loss)

C., Hsu Y

Local injection is less critical for TB-500 than for BPC-157

Several reasons may explain the observation that the mean treatment difference was 12.5% in STEP 1 and 8.7% in SELECT

It is typically administered subcutaneously at 50100 mg daily in timed cycles, with noticeable energy and body-composition changes emerging within 38 weeks and side effects generally mild and transient

The study findings have not gone through peer reviews yet, and federal regulators with the U.S